Lipids

Ethynyl Estradiol-2,4,16,16-d4 is a synthetic deuterium-labeled steroid with high estrogenic potency.

Etidronic Acid-d3 Sodium Salt is labeled Etidronic acid. Etidronic acid is used as a calcium regulator and is a bisphosphonate antiresorptive agent.

Farnesyl alcohol azide acts as a replacement for endogenously-produced farnesyl alcohol and becomes attached to proteins through normal biological processes in cells or animals. The terminal azide group can then be used in simple chemical linking

Farnesyl alcohol azide acts as a replacement for endogenously-produced farnesyl alcohol and becomes attached to proteins through normal biological processes in cells or animals. The terminal azide group can then be used in simple chemical linking

FTA has shown potent and specifc inhibition of methyl esterification of farnesylated and geranylgeranylated proteins. It has inhibited Ca2+ influx through non-voltage-gated Ca2+ channels. FTA also has the property to be a TRPA1 agonist.

FTA has shown potent and specifc inhibition of methyl esterification of farnesylated and geranylgeranylated proteins. It has inhibited Ca2+ influx through non-voltage-gated Ca2+ channels. FTA also has the property to be a TRPA1 agonist.

FTA has shown potent and specifc inhibition of methyl esterification of farnesylated and geranylgeranylated proteins. It has inhibited Ca2+ influx through non-voltage-gated Ca2+ channels. FTA also has the property to be a TRPA1 agonist.

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice